Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
CVRx's Capital Expenditure for the
three
months ended in Mar. 2024 was $-0.92 Mil. Its Revenue for the
three
months ended in Mar. 2024 was $10.77 Mil.
Hence, CVRx's Capex-to-Revenue for the
three
months ended in Mar. 2024 was 0.09.
CVRx Capex-to-Revenue Historical Data
The historical data trend for CVRx's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CVRx's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVRx's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where CVRx's Capex-to-Revenue falls into.
CVRx Capex-to-Revenue Calculation
CVRx's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVRx (NAS:CVRX) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
CVRx Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of CVRx's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CVRX has been successfully added to your 